



(11)

EP 2 234 625 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 31/765 (2006.01) A61P 21/00 (2006.01)

(86) International application number:
PCT/US2008/087185

(48) Corrigendum issued on:
30.10.2013 Bulletin 2013/44

(87) International publication number:
WO 2009/079562 (25.06.2009 Gazette 2009/26)

(45) Date of publication and mention
of the grant of the patent:
11.09.2013 Bulletin 2013/37

(21) Application number: **08861170.2**

(22) Date of filing: **17.12.2008**

(54) **COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING SKELETAL MUSCLE DEFICIENCIES**

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG UND PRÄVENTION VON
SKELETTMUSKEL-MÄNGELN

COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT ET LA PRÉVENTION DE DÉFICIENCES
DES MUSCLES SQUELETTIQUES

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**

• **MARKHAM, Bruce**
Novi, Michigan 48374 (US)

(30) Priority: **17.12.2007 US 14304 P**

(74) Representative: **Glawe, Delfs, Moll**
Patent- und Rechtsanwälte
Rothenbaumchaussee 58
20148 Hamburg (DE)

(43) Date of publication of application:
06.10.2010 Bulletin 2010/40

(56) References cited:
WO-A1-2006/100017 WO-A2-2006/091941
US-A- 5 605 687 US-A1- 2006 012 016
US-A1- 2007 237 740

(60) Divisional application:
13183738.7

(73) Proprietors:
• **The Regents of the University of Michigan**
Ann Arbor, MI 48109-2590 (US)
• **Phrixus Pharmaceuticals, Inc.**
Ann Arbor, MI 48109 (US)

• **COLLINS ET AL: "Structural and functional
recovery of electroporabilized skeletal muscle
in-vivo after treatment with surfactant poloxamer
188", BIOCHIMICA ET BIOPHYSICA ACTA, vol.
1768, no. 5, 11 April 2007 (2007-04-11), pages
1238-1246, XP022026705, BIOMEMBRANES,
AMSTERDAM, NL ISSN: 0005-2736, DOI:
10.1016/J.BBAMEM.2007.01.012**

(72) Inventors:
• **NG, Rainer**
Seattle, Washington 98125 (US)
• **METZGER, Joseph M.**
Minneapolis, Minnesota 55414 (US)
• **REEVE, Lorraine**
Dexter, Michigan 48130 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 234 625 B8

- **SCHEUERBRANDT G: "Approaching therapies for boys with Duchenne muscular dystrophy. Parent Project Muscular Dystrophy. Annual Conference in Cincinnati/Ohio, 13-16 July 2006", ACTA MYOLOGICA, vol. 25, no. 2, 1 October 2006 (2006-10-01), pages 77-97, XP001539612, GAETANO CONTE ACADEMY FOR THE STUDY OF STRIATED MUSCLE DISEASES, NAPLES; IT ISSN: 1128-2460**
- **RYALL JAMES G ET AL: "The membrane sealant poloxamer reduces membrane permeability in tibialis anterior muscles from dystrophic mdx mice", FASEB JOURNAL, vol. 21, no. 6, A945, April 2007 (2007-04) , XP002627660, & EXPERIMENTAL BIOLOGY 2007 ANNUAL MEETING; WASHINGTON, DC, USA; APRIL 28 -MAY 02, 2007 ISSN: 0892-6638**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification